

# Peter G Rose

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1295366/peter-g-rose-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224  
papers

2,165  
citations

27  
h-index

44  
g-index

239  
ext. papers

2,574  
ext. citations

3  
avg, IF

4.86  
L-index

#	Paper	IF	Citations
224	Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer.. <i>Gynecologic Oncology Reports</i> , <b>2022</b> , 40, 100951	1.3	
223	Life or limb: an international qualitative study on decision making in sarcoma surgery during the COVID-19 pandemic. <i>BMJ Open</i> , <b>2021</b> , 11, e047175	3	
222	Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , <b>2021</b> , 38, 100876	1.3	0
221	Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 194-201	4.9	6
220	Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 211-220	4.9	7
219	Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors. <i>Journal of Ovarian Research</i> , <b>2021</b> , 14, 55	5.5	1
218	Posterior-First Two-Stage Approach to En Bloc Resection of Locally Recurrent Rectal Cancer Involving the Pelvic Sidewall. <i>Diseases of the Colon and Rectum</i> , <b>2021</b> , 64, e465-e470	3.1	
217	Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 389-395	4.9	5
216	Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1021-1030	3.5	1
215	Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , <b>2021</b> , 50, 101844	1.9	4
214	Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 160, 45-50	4.9	4
213	Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis. <i>Gynecologic Oncology</i> , <b>2021</b> , 160, 405-412	4.9	3
212	Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy. <i>Journal of Surgical Oncology</i> , <b>2021</b> , 123, 1292-1298	2.8	0
211	Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 652683	5.3	
210	Modified Frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , <b>2021</b> , 162, 368-374	4.9	2
209	Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma. <i>Gynecologic Oncology Reports</i> , <b>2021</b> , 37, 100840	1.3	0
208	Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 162, 645-651	4.9	3

207	Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers. <i>Immunotherapy</i> , <b>2021</b> , 13, 1179-1192	3.8	2
206	Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 511-516 <sup>4,9</sup>		
205	High TGF- $\beta$ signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition.. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 101	9.8	4
204	Outcome of Sacroplvic Resection and Reconstruction Based on a Novel Classification System. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2020</b> , 102, 1956-1965	5.6	4
203	Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 309-315	4.9	2
202	A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 794-802	4.9	10
201	Use of prophylactic closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomy. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 223, 731.e1-731.e9	6.4	7
200	Comparison of Porous Tantalum Acetabular Implants and Harrington Reconstruction for Metastatic Disease of the Acetabulum. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2020</b> , 102, 1239-1247	5.6	13
199	Landmark studies of therapeutic vaccination in cervical and ovarian cancers. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1549-1550	21.7	1
198	Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicin. <i>Anti-Cancer Drugs</i> , <b>2020</b> , 31, 747-750	2.4	2
197	Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 905	3.2	5
196	Team Approach: Oncologic Sacrectomy. <i>JBJS Reviews</i> , <b>2020</b> , 8, e1900226	2.6	0
195	Exophytic Lumbar Vertebral Body Mass in an Adult with Back Pain. <i>American Journal of Neuroradiology</i> , <b>2020</b> , 41, 1786-1790	4.4	2
194	Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 699-705	4.9	6
193	Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing. <i>Gynecologic Oncology Reports</i> , <b>2019</b> , 30, 100499	1.3	5
192	Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , <b>2019</b> , 133, 245-254	4.9	17
191	Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 1126-1133	3.5	4
190	Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer. <i>Journal of Ovarian Research</i> , <b>2019</b> , 12, 112	5.5	8

189	Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing. <i>Anti-Cancer Drugs</i> , <b>2019</b> , 30, 636-639	2.4	1
188	A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 247-252	4.9	35
187	Management Strategies for Recurrent Endometrial Cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 873-885	3.5	33
186	How Does the Level of Nerve Root Resection in En Bloc Sacrectomy Influence Patient-Reported Outcomes?. <i>Clinical Orthopaedics and Related Research</i> , <b>2017</b> , 475, 607-616	2.2	36
185	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2017</b> , 144, 459-467	4.9	45
184	Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 452-458	3.5	18
183	Adverse post-operative outcomes in Jehovah's witnesses with gynecologic cancer within 30 days of surgery: A single institution review of 36 cases. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 22, 32-36	1.3	3
182	Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions. <i>Journal of Gynecologic Oncology</i> , <b>2017</b> , 28, e38	4	6
181	Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 907-911	3.5	4
180	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 85-91	4.9	49
179	Atypical Notochordal Cell Tumors: A Series of Notochordal-derived Tumors That Defy Current Classification Schemes. <i>American Journal of Surgical Pathology</i> , <b>2017</b> , 41, 39-48	6.7	16
178	Outcomes and Complications of Reconstruction with Use of Free Vascularized Fibular Graft for Spinal and Pelvic Defects Following Resection of a Malignant Tumor. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2017</b> , 99, e69	5.6	28
177	How Does the Level of Sacral Resection for Primary Malignant Bone Tumors Affect Physical and Mental Health, Pain, Mobility, Incontinence, and Sexual Function?. <i>Clinical Orthopaedics and Related Research</i> , <b>2016</b> , 474, 687-96	2.2	45
176	Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>2016</b> , 26, 1048-52	3.5	13
175	A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 204-9	4.9	35
174	Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. <i>Anticancer Research</i> , <b>2016</b> , 36, 6161-6164	2.3	34
173	The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone. <i>Journal of Gynecologic Oncology</i> , <b>2016</b> , 27, e19	4	11
172	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. <i>Gynecologic Oncology</i> , <b>2016</b> , 143, 294-301	4.9	24

171	Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 529-33	4.9	17
170	Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 407-12	4.9	9
169	Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2015</b> , 213, 350.e1-10	6.4	9
168	Seromuscular Colonic Flap for Intrapelvic Soft-Tissue Coverage: A Reconstructive Option for Plastic Surgeons When Traditionally Used Flaps Are Not Available. <i>Case Reports in Surgery</i> , <b>2015</b> , 2015, 563641	0.5	0
167	Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2136-42	2.2	96
166	Combination of a fillet flap, free tissue transfer, and autologous tissue grafts in pelvic reconstruction following retroperitoneal sarcoma: a case report. <i>Microsurgery</i> , <b>2015</b> , 35, 320-3	2.1	
165	A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 240-5	4.9	39
164	Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 235-9	4.9	20
163	Racial disparity in the 30-day morbidity and mortality after surgery for endometrial cancer. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 510-5	4.9	14
162	Distal Femoral Subchondral Metastasis Mistaken for an Insufficiency Fracture and Treated with Total Knee Arthroplasty: A Case Report. <i>JBJS Case Connector</i> , <b>2014</b> , 4, e91	0.4	
161	Extended sacropelvic resection for locally recurrent rectal cancer: can it be done safely and with good oncologic outcomes?. <i>Diseases of the Colon and Rectum</i> , <b>2014</b> , 57, 47-55	3.1	38
160	Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 1603-6	3.5	7
159	Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma. <i>Anti-Cancer Drugs</i> , <b>2013</b> , 24, 986-8	2.4	4
158	The value of preoperative biopsy in the management of solid presacral tumors. <i>Diseases of the Colon and Rectum</i> , <b>2013</b> , 56, 756-60	3.1	40
157	Surgical technique: Porous tantalum reconstruction for destructive nonprimary periacetabular tumors. <i>Clinical Orthopaedics and Related Research</i> , <b>2012</b> , 470, 594-601	2.2	42
156	Thymoma and Thymic Carcinoma <b>2012</b> , 279-301		
155	Male Breast Cancer <b>2012</b> , 233-241		
154	Myeloproliferative Neoplasms: Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis <b>2012</b> , 647-658		1

- 153 Glioma and Other Neuroepithelial Neoplasms **2012**, 767-794
- 152 Langerhans Cell Histiocytosis of the Central Nervous System **2012**, 715-720
- 151 Parathyroid Carcinoma **2012**, 201-209 1
- 150 Metaplastic Breast Carcinoma **2012**, 211-216 0
- 149 Extraovarian Primary Peritoneal Carcinomas **2012**, 485-495
- 148 Fallopian Tube Cancer **2012**, 531-539
- 147 Gastrointestinal Stromal Tumors **2012**, 465-483
- 146 Borderline Tumors and Other Rare Epithelial Tumors of the Ovary **2012**, 497-506
- 145 Nasopharyngeal Carcinoma in Nonendemic Populations **2012**, 131-150
- 144 Adenoid Cystic Carcinoma of the Breast **2012**, 217-224
- 143 Large Cell Neuroendocrine Carcinoma **2012**, 343-353
- 142 Uncommon Cancers of the Bladder **2012**, 23-33 2
- 141 Germ Cell Tumors of the Ovary **2012**, 519-530 2
- 140 Hematological Malignancies Uncommon Presentations of Plasma Cell Dyscrasias **2012**, 627-635
- 139 Atypical and Malignant Meningiomas **2012**, 733-745
- 138 Phyllodes Tumor of the Breast **2012**, 243-256 2
- 137 Uncommon Tumors of the Esophagus **2012**, 373-388 1
- 136 Cancers of the Small Bowel **2012**, 441-451 1

135	Uncommon Tumors of the Kidney <b>2012</b> , 1-22		2
134	Uncommon Cancers of the Stomach <b>2012</b> , 389-408		
133	Tantalum acetabular cups provide secure fixation in THA after pelvic irradiation at minimum 5-year followup. <i>Clinical Orthopaedics and Related Research</i> , <b>2012</b> , 470, 3041-7	2.2	34
132	Large (36 or 40-mm) femoral heads decreased the rate of dislocation after revision total hip arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2012</b> , 94, 2095	5.6	5
131	Uncommon Pediatric Brain Tumors <b>2012</b> , 927-942		
130	Pineal Parenchymal Tumors <b>2012</b> , 813-821		
129	Uncommon Pediatric Tumors of the Thorax <b>2012</b> , 877-901		
128	Uncommon Adrenal Tumors in Children and Adolescents <b>2012</b> , 903-914		1
127	Rare Tumors of the Testis and Paratesticular Tissues <b>2012</b> , 77-96		2
126	Adrenal Neoplasms <b>2012</b> , 163-187		
125	Uncommon Cancers of the Thyroid <b>2012</b> , 189-200		
124	Non-Hodgkin Lymphoma of the Breast <b>2012</b> , 225-232		
123	Carcinosarcoma of the Breast <b>2012</b> , 257-269		
122	Tubular Carcinoma <b>2012</b> , 271-277		
121	Primary Sarcomas of the Lung <b>2012</b> , 303-317		
120	Mesotheliomas <b>2012</b> , 319-334		
119	Primary Melanoma of the Lung <b>2012</b> , 335-341		
118	Bronchioloalveolar Carcinoma of the Lung <b>2012</b> , 355-363		

117 Primary Adenoid Cystic Carcinoma of the Lung **2012**, 365-372

116 Unusual Cancers of the Pancreas **2012**, 409-421

115 Urethral Cancer **2012**, 35-46

114 Uncommon Hepatobiliary Tumors **2012**, 423-440

113 Unusual Tumors of the Colon, Rectum, And Anus **2012**, 453-463

112 Stromal Tumors of the Ovary **2012**, 507-518

1

111 Uncommon Cancers of the Prostate **2012**, 47-75

2

110 Tumors of the Cervix **2012**, 567-585

109 Tumors of the Vulva and Vagina **2012**, 587-599

0

108 Rare Acute Leukemias **2012**, 601-609

107 Unusual Myelodysplastic Syndromes and Myeloproliferative Neoplasms **2012**, 613-616

106 Rare B Cell Lymphoproliferative Disorders **2012**, 617-626

105 Rare Bone Marrow Failure Conditions **2012**, 637-646

104 Uncommon Tumors of the Oral Cavity and Adjacent Structures **2012**, 97-117

103 Esthesioneuroblastoma **2012**, 151-162

102 Rare T Cell Lymphomas **2012**, 659-666

101 Unusual Cutaneous Malignancies **2012**, 667-683

100 Unusual Melanomas **2012**, 691-708



99 Primary Melanotic Tumors of the Central Nervous System **2012**, 709-714

98 Chordomas **2012**, 721-732

1

97 Primary Central Nervous System Lymphoma **2012**, 747-757

96 Choroid Plexus Papilloma and Carcinoma **2012**, 759-766

95 Medulloblastoma in Adults **2012**, 795-811

94 Craniopharyngiomas **2012**, 823-834

93 Ophthalmic Cancers **2012**, 835-846

92 Introduction to Rare Cancers of Childhood **2012**, 847-849

91 Uncommon Tumors of the Gastrointestinal Tract in Children **2012**, 851-865

90 Rare Pediatric Malignancies of the Head And Neck **2012**, 867-875

89 Uncommon Pediatric Genitourinary Tumors **2012**, 915-926

88 Malignant Tumors of the Skin and Subcutaneous Tissue in Children **2012**, 943-957

87 Rare Tumors of the Larynx **2012**, 119-130

86 Sacral tumor resection: the effect of surgical staging on patient outcomes, resource management, and hospital cost. *Spine*, **2011**, 36, 1570-8 3.3 27

85 A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. *Gynecologic Oncology*, **2011**, 122, 111-5 4.9 86

84 Giant cell tumor of bone: risk factors for recurrence. *Clinical Orthopaedics and Related Research*, **2011**, 469, 591-9 2.2 234

83 Recurrent giant cell tumor of long bones: analysis of surgical management. *Clinical Orthopaedics and Related Research*, **2011**, 469, 1181-7 2.2 91

82 Surgical management of 121 benign proximal fibula tumors. *Clinical Orthopaedics and Related Research*, **2010**, 468, 3056-62 2.2 30

81	Do surgical margin and local recurrence influence survival in soft tissue sarcomas?. <i>Clinical Orthopaedics and Related Research</i> , <b>2010</b> , 468, 3003-11	2.2	90
80	Morbidity and functional status of patients with pelvic neurogenic tumors after wide excision. <i>Clinical Orthopaedics and Related Research</i> , <b>2010</b> , 468, 2948-53	2.2	10
79	Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 1281-3	3.5	30
78	Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 114-9	4.9	7
77	Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2006</b> , 102, 236-9	4.9	10
76	Phyllodes Tumor of the Breast <b>2006</b> , 209-217		3
75	Uncommon Pediatric Brain Tumors <b>2006</b> , 798-809		1
74	Esthesioneuroblastoma <b>2006</b> , 133-142		
73	Urethral Cancer <b>2006</b> , 27-37		1
72	Uncommon Cancers of the Prostate <b>2006</b> , 38-65		
71	Male Breast Cancer <b>2006</b> , 201-208		1
70	Unusual Tumors of the Colon, Rectum and Anus <b>2006</b> , 401-409		
69	Tumors of the Vulva and Vagina <b>2006</b> , 521-531		
68	Carcinoid Tumors of the Lung <b>2006</b> , 307-312		1
67	Tumors of the Cervix <b>2006</b> , 501-520		
66	Cancer of the Small Bowel <b>2006</b> , 391-400		2
65	Primary Central Nervous System Lymphoma <b>2006</b> , 657-666		
64	Mesotheliomas <b>2006</b> , 279-292		

63 Bronchioloalveolar Carcinoma of the Lung **2006**, 313-320

62 Borderline Tumors and Other Rare Epithelial Tumors of the Ovary **2006**, 447-454

61 Germ Cell Tumors of the Ovary **2006**, 467-476

60 Mucoepidermoid Tumors of the Lung **2006**, 329-335

59 Uterine Sarcomas and Unusual Endometrial Carcinomas **2006**, 485-500

58 Uncommon Tumors of the Oral Cavity and Adjacent Structures **2006**, 87-101

57 Uncommon Tumors of the Gastrointestinal Tract in Children **2006**, 749-759

56 Primary Melanoma of the Lung **2006**, 293-297

7

55 Carcinosarcoma of the Breast **2006**, 218-229

1

54 Atypical and Malignant Meningiomas **2006**, 639-648

2

53 Uncommon Pediatric Genitourinary Tumors **2006**, 760-774

52 Nasopharyngeal Carcinoma in Non-endemic Populations **2006**, 113-132

51 Stromal Tumors of the Ovary **2006**, 455-466

50 Malignant Tumors of the Skin and Subcutaneous Tissue in Children **2006**, 810-818

49 Thymoma and Thymic Carcinoma **2006**, 237-256

48 Chordomas **2006**, 614-625

6

47 Glioma and Other Neuroepithelial Neoplasms **2006**, 674-694

46 Uncommon Tumors of the Kidney **2006**, 1-17

45	Uncommon Cancers of the Thyroid <b>2006</b> , 165-173	1
44	Primary Lymphomas of the Lung <b>2006</b> , 257-263	1
43	Extra-ovarian Primary Peritoneal Carcinomas <b>2006</b> , 437-446	
42	Uncommon Cancers of the Esophagus <b>2006</b> , 337-351	1
41	Adenoid Cystic Carcinoma of the Breast <b>2006</b> , 187-193	2
40	Choroid Plexus Papilloma and Carcinoma <b>2006</b> , 667-673	
39	Neoplastic Disorders of the Adrenal Glands <b>2006</b> , 143-164	
38	Tubular Carcinoma <b>2006</b> , 230-235	1
37	Primary Sarcomas of the Lung <b>2006</b> , 264-278	2
36	Uncommon Endocrine Tumors in Children and Adolescents <b>2006</b> , 775-797	1
35	Uncommon Pediatric Tumors of the Thorax <b>2006</b> , 732-748	
34	Gestational Trophoblastic Diseases <b>2006</b> , 532-542	1
33	Craniopharyngiomas <b>2006</b> , 705-711	
32	Primary Adenoid Cystic Carcinoma of the Lung <b>2006</b> , 321-328	
31	Unusual Cutaneous Malignancies <b>2006</b> , 577-588	
30	Melanotic Lesions of the Meninges <b>2006</b> , 605-609	
29	Ophthalmic Cancers <b>2006</b> , 712-720	
28	Non-Hodgkin Lymphoma of the Breast <b>2006</b> , 194-200	

27	Uncommon Cancers of the Stomach <b>2006</b> , 352-366		0
26	LangerhansSCell Histiocytosis of the Central Nervous System <b>2006</b> , 610-613		1
25	Metaplastic Breast Carcinoma <b>2006</b> , 181-186		1
24	Unusual Pancreatic Tumors <b>2006</b> , 367-382		
23	Cancer of the Appendix <b>2006</b> , 410-417		
22	Gastrointestinal Stromal Tumors <b>2006</b> , 418-429		
21	Meningeal Sarcomas <b>2006</b> , 626-637		1
20	Uncommon Cancers of the Bladder <b>2006</b> , 18-26		2
19	Rare Leukemias <b>2006</b> , 543-554		
18	Large Cell Neuroendocrine Carcinoma <b>2006</b> , 298-306		1
17	Rare Tumors of the Testis and Paratesticular Tissues <b>2006</b> , 66-85		1
16	Uncommon Hepatobiliary Tumors <b>2006</b> , 383-390		
15	Fallopian Tube Cancer <b>2006</b> , 477-484		1
14	Rare Tumors of the Larynx <b>2006</b> , 102-112		1
13	Primary Intracranial Germ Cell Tumors <b>2006</b> , 649-656		1
12	Medulloblastoma and CNS Primitive Neuroectodermal Tumors <b>2006</b> , 695-704		
11	Small Cell Carcinomas of the Gastrointestinal Tract <b>2006</b> , 430-435		1
10	A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 296-300	4.9	34

9	Stage IIB-IVA cancer of the cervix. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2003</b> , 9, 404-14	2.2	4
8	Phase II study of paclitaxel and valsopodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2975-82	2.2	86
7	Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis. <i>Journal of Clinical Pharmacology</i> , <b>2000</b> , 40, 296-300	2.9	33
6	Chemoradiotherapy: the new standard care for invasive cervical cancer. <i>Drugs</i> , <b>2000</b> , 60, 1239-44	12.1	25
5	Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 2676-80	2.2	181
4	Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. <i>Cancer</i> , <b>1989</b> , 64, 1508-136.4		180
3	Uncommon Presentations of Plasma Cell Dyscrasias569-575		
2	Rare Pediatric Malignancies of the Head and Neck721-731		
1	Rare Lymphomas555-568		1